Content for healthcare professionals only

View all Platforms Cardiology

Topics Content Type Videos Articles Journals Broadcasts Education Podcasts News Journals AER CFR ECR ICR3 JAPSC USC Faculty Events Upcoming Events Radcliffe Events All Events Resource Hubs Empagliflozin in the Treatment of Chronic Heart Failure Pulmonary Embolism Pulsed Field Ablation

Radcliffe Platforms

Radcliffe Group Cardiology Vascular CVRM Medical Education

Content for healthcare professionals only

Content Type

Events

Resource Hubs

Images

Filter by

Topics

Newer than

Figure 2 Ajmaline-induced Brugada Type 1 ECG in a Patient with Inferior ER Pattern Presenting with Sudden Cardiac Arrest

Figure 2: Ajmaline-induced Brugada Type 1 ECG in a Patient with Inferior ER Pattern, Presenting with Sudden Cardiac Arrest

Table 1 Genetic Mutations Associated With Arrhythmogenic Right Ventricular Cardiomyopathy-Dysplasia

Table 1: Genetic Mutations Associated With Arrhythmogenic Right Ventricular Cardiomyopathy-Dysplasia

Figure 1 Phospolamban Protein Expression and Localisation

Figure 1: Phospolamban Protein Expression and Localisation

Table 2 Clinical Characteristics of Arrhythmogenic Ventricular Cardiomyopathy

Table 2: Clinical Characteristics of Arrhythmogenic Ventricular Cardiomyopathy

Figure 2 Structural Phenotypes of Arrhythmogenic Cardiomyopathy

Figure 2: Structural Phenotypes of Arrhythmogenic Cardiomyopathy

Table 3 Revised 2010 Task Force Criteria for Diagnosis of ARVC/D

Table 3: Revised (2010) Task Force Criteria for Diagnosis of ARVC/D

Figure 3 Electrical Phenotypes of Arrhythmogenic Cardiomyopathy

Figure 3: Electrical Phenotypes of Arrhythmogenic Cardiomyopathy

Table 1 Summary Of Antiarrhythmic Drug Dosages Applied In Clinical Trials

Table 1: Summary Of Antiarrhythmic Drug Dosages Applied In Clinical Trials

Figure 1 Recommendations For Treating Inappropriate And Appropriate Implantable Cardioverter Defibrillator Shocks

Figure 1: Recommendations For Treating Inappropriate And Appropriate Implantable Cardioverter Defibrillator Shocks

Figure 1 Forest Plot For Hazard Ratio Of Mortality For A Appropriate Shock Versus No Shock And B Inappropriate Shock Versus No Shock

Figure 1: Forest Plot For Hazard Ratio Of Mortality For (A) Appropriate Shock Versus No Shock And (B) Inappropriate Shock Versus No Shock

Figure 2 Risk Of Death After First Shock Compared With No Shock Group In The ALTITUDE Study

Figure 2: Risk Of Death After First Shock Compared With No Shock Group In The ALTITUDE Study

Figure 3 Survival Rates By Rhythm And Implantable Cardioverter Defibrillator Therapy Type

Figure 3: Survival Rates By Rhythm And Implantable Cardioverter Defibrillator Therapy Type